VR Logo

In Focus: Growth Pills

Ind-Swift is in the process of tapping the non-regulated markets for growth

Chandigarh-based Ind Swift Group is a major player in anti-infectives and steroids & hormones segments and is expanding into speciality segments of anti-diabetes, gynaecology, cardiovascular and anti-depressant segments.

The group has presence in 45 countries with two listed entities - Ind-Swift Limited (Idirect Code: INDSW), manufacturers of finished dosages, and Ind-Swift Laboratories, manufacturers of active pharmaceutical ingredients and advanced intermediates, and one wholly-owned subsidiary in the US. Currently, 30 per cent of the group's turnover comes from exports.

The company's top 10 brands constitute over 50 per cent of its turnover. Ind Swift is one of the first companies in India to bag the DGCI nod to manufacture and market the coveted citalopram drug in API and finished dosages.

The company has inked a pact with Unichem (Idirect Code: UNILAB) to manufacture this drug for the latter's GMP (good manufacturing practices)-compliant plant at Parwanoo (Himachal Pradesh). Ind Swift has multipurpose, multi-location manufacturing set-ups that are spread across Himachal Pradesh, Haryana and Jammu and Kashmir.

It is planning to launch its formulations in foreign markets by filing two patents for its products based on novel drug delivery system (NDDS). These patents are for the products in the anti-histamines and anti-infectives segments. While the company is developing several drugs on NDDS model, it is also in the process of introducing its products in non-regulated markets. Ind Swift's has an annual capacity to manufacture 2,300 million tablets, 64 million ampoules, 27 million vials, 84 million capsules, 18 million dermatological products and 62 million oral liquid bottles. It is into CRAMS (contract research and manufacturing) in a big way and does contract research for domestic and global clients. The company also brings out a health publication Trendz.